Combined analysis of a serum mRNA/miRNA marker signature and CA 19‐9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12676 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Malte Buchholz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, Philipps-University and University Hospital Marburg, Marburg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, CA-19-9 Antigen, Neoplasm Recurrence, Local, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EU TRANSCAN.
Abstract (Originalsprache)
Background and Aims Timely and accurate detection of tumor recurrence in pancreatic ductal adenocarcinoma (PDAC) patients is an urgent and unmet medical need. This study aimed to develop a noninvasive molecular diagnostic procedure for the detection of recurrence after PDAC resection based on quantification of circulating mRNA and miRNA biomarkers in serum samples.
Methods
In a multicentric study, serum samples from a total of 146 patients were prospectively collected after resection. Samples were classified into a “No Evidence of Disease” and a “Recurrence” group based on clinical follow‐up data. A multianalyte biomarker panel was composed of mRNAs and miRNA markers and simultaneously analyzed in serum samples using custom microfluidic qPCR arrays (TaqMan array cards). A diagnostic algorithm was developed combining a 7‐gene marker signature with CA19‐9 data.
Results
The best‐performing marker combination achieved 90% diagnostic accuracy in predicting the presence of tumor recurrence (98% sensitivity; 84% specificity), clearly outperforming the singular CA 19‐9 analysis. Moreover, time series data obtained by analyzing successively collected samples from 5 patients during extended follow‐up suggested that molecular diagnosis has the potential to detect recurrence earlier than routine clinical procedures.
Conclusions
TaqMan array card measurements were found to be biologically valid and technically reproducible. The BioPac multianalyte marker panel is capable of sensitive and accurate detection of recurrence in patients resected for PDAC using a simple blood test. This could allow a closer follow‐up using shorter time intervals than currently used for imaging, thus potentially prompting an earlier work‐up with additional modalities to allow for earlier therapeutic intervention. This study provides a promising approach for improved postoperative monitoring of resected PDAC patients, which is an urgent and unmet clinical need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, Philipps-University and University Hospital Marburg, Marburg, Germany.
- Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
- Fakultät Informatik, Biomedizinische Informatik, Technische Hochschule Ingolstadt, Ingolstadt, Germany.
- Chirurgische Klinik / Europäisches Pankreaszentrum, Universitätsklinikum Heidelberg, Heidelberg, Germany.
- Molecular Epidemiology and Predictive Tumor Markers Group, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBERONC, Madrid, Spain.
- Centre for Applied Research on Cancer, University of Verona - Policlinico G.B. Rossi, Verona, Italy.
ORCID-Profile: Malte Buchholz
Förderung
- EU TRANSCAN
Zitieren
APA
Buchholz, M., Lausser, L., Schenk, M., Earl, J., Lawlor, R. T., Scarpa, A., Sanjuanbenito, A., Carrato, A., Malats, N., Tjaden, C., Giese, N. A., Büchler, M., Hackert, T., Kestler, H. A., Gress, T. M., & BioPaC consortium (2025). Combined analysis of a serum mRNA/miRNA marker signature and CA 19‐9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12676
Vancouver
Buchholz M, Lausser L, Schenk M, Earl J, Lawlor RT, Scarpa A, et al. Combined analysis of a serum mRNA/miRNA marker signature and CA 19‐9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12676
BibTeX
@article{Buchholz2025,
author = {Buchholz, Malte and Lausser, Ludwig and Schenk, Miriam and Earl, Julie and Lawlor, Rita T and Scarpa, Aldo and Sanjuanbenito, Alfonso and Carrato, Alfredo and Malats, Nuria and Tjaden, Christine and Giese, Nathalia A and Büchler, Markus and Hackert, Thilo and Kestler, Hans A and Gress, Thomas M and BioPaC consortium, BioPaC consortium},
title = {Combined analysis of a serum mRNA/miRNA marker signature and CA 19‐9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12676}
}
EUVIMED